

REMARKS


Applicants have amended the specification for purposes of adding the priority information. Applicants have attached an Abstract on a separate sheet of paper as required by US practice.

Claims 1-157 have been canceled. Claims 158-247 are newly-added and are fully supported by the specification.

Entry of the amendment prior to the examination of the application and calculation of the filing fee is respectfully requested.

The Commissioner is hereby authorized in this, concurrent, and future replies, to charge any fees or credit any overpayment, particularly including any fees required under 37 CFR Sect 1.16 or 1.17, and any necessary extension of time fees, to deposit Account No. 07-1392.

Respectfully submitted,



Robert J. Smith
Attorney for Applicant
Registration No. 40,820

Date: September 8, 2006
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709-3398
Phone: 919-483-9616
Facsimile: 919-483-7988